Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Setembro 2023 - 8:30AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases, today announced that management will
present at the H.C. Wainwright 25th Annual Global Investment
Conference on Monday, September 11, 2023, at 9:30 am ET in New
York.
The live webcast of the presentation can be
accessed by visiting the Events and Presentations section of the
Company’s website: https://ir.protaratx.com. The webcast will be
archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to advancing transformative
therapies for people with cancer and rare diseases. Protara’s
portfolio includes its lead program, TARA-002, an investigational
cell-based therapy being developed for the treatment of non-muscle
invasive bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement for
patients dependent on parenteral nutrition. For more information,
visit www.protaratx.com.
Company Contact:Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Protara Therapeutics (NASDAQ:TARA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024